Capmany G, Querol S, Cancelas J A, García J
Cryobiology and Cell Therapy Department and Barcelona Cord Blood Bank, Institut de Recerca Oncològica, Barcelona, Spain.
Haematologica. 1999 Aug;84(8):675-82.
The use of ex vivo expanded cells has been suggested as a possible means to accelerate the speed of engraftment in cord blood (CB) transplantation. The aim of this study was to fix the optimal condition for the generation of committed progenitors without affecting the stem cell compartment.
Analysis of the effects of FLT3-L and MIP-1alpha when combined with SCF, IL-3 and IL-6, in short-term (6 days), serum-free expansion cultures of CB-selected CD34+ cells.
An important expansion was obtained that ranged between 8-15 times for CFU-GM, 21-51 times for the BFU-E/CFU-Mix population and 11 to 30 times for CD34+ cells assessed by flow cytometry. From the combinations tested, those in which FLT3-L was present had a significant increase in the expansion of committed progenitors, while the presence of MIP-1alpha had a detrimental effect on the generation of more differentiated cells. However, stem cell candidates assessed by week 5 CAFC assay could be maintained in culture when both MIP-1a and FLT3-L were present (up to 91% recovery). This culture system was also able to expand megakaryocytic precursors as determined by the co-expression of CD34 and CD61 antigens (45-70 times), in spite of the use of cytokines non-specific for the megakaryocytic lineage.
The results obtained point to the combination of SCF, IL-3, IL-6, FLT3-L and MIP-1alpha as the best suited for a pre-clinical short-term serum-free static ex vivo expansion protocol of CB CD34+ cells, since it can generate large numbers of committed progenitor cells as well as maintaining week 5 CAFC.
有人提出使用体外扩增细胞作为加速脐血(CB)移植中植入速度的一种可能方法。本研究的目的是确定在不影响干细胞区室的情况下生成定向祖细胞的最佳条件。
分析FLT3-L和MIP-1α与SCF、IL-3和IL-6联合使用时,对CB选择的CD34+细胞进行短期(6天)无血清扩增培养的影响。
通过流式细胞术评估,CFU-GM扩增了8至15倍,BFU-E/CFU-Mix群体扩增了21至51倍,CD34+细胞扩增了11至30倍。在所测试的组合中,存在FLT3-L的组合中定向祖细胞的扩增显著增加,而MIP-1α的存在对更多分化细胞的生成有不利影响。然而,当同时存在MIP-1α和FLT3-L时,通过第5周CAFC试验评估的干细胞候选细胞可以在培养中维持(恢复率高达91%)。尽管使用了对巨核细胞系非特异性的细胞因子,但该培养系统仍能够扩增由CD34和CD61抗原共表达所确定的巨核细胞前体(45至70倍)。
所得结果表明,SCF、IL-3、IL-6、FLT3-L和MIP-1α的组合最适合用于CB CD34+细胞的临床前短期无血清静态体外扩增方案,因为它可以产生大量定向祖细胞并维持第5周CAFC水平。